NovaBay Pharmaceuticals, Inc. Supports Legislation to Attack Antibiotic Resistance

Published: Jun 17, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

EMERYVILLE, Calif., June 17, 2013 (GLOBE NEWSWIRE) -- Dr. Ron Najafi, Chairman and Chief Executive Officer of NovaBay Pharmaceuticals, Inc. (NYSE:NBY) today announced NovaBay's support for legislation by U.S. Rep. Jim Matheson (D-UT) to attack the growing crisis of antibiotic resistance. NovaBay is a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with first-in-class compounds such as its proprietary Aganocides®.

Help employers find you! Check out all the jobs and post your resume.

Back to news